Kite Pharma Completes Filing for CAR-T Therapy with FDA – Yahoo Finance
Yahoo Finance |
Kite Pharma Completes Filing for CAR–T Therapy with FDA
Yahoo Finance We note that axicabtagene ciloleucel is Kite Pharma's anti-CD19 chimeric antigen receptor (CAR) T cell therapy. The BLA is for the treatment for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who are ineligible for … Kite keeps pressure on Novartis with CAR–T filing Kite Pharma (KITE) Gaining After Presenting At AACR This Weekend Kite Pharma Inc (KITE) Announces Submission of Biologics License Application to FDA for Axicabtagene Ciloleucel |
